Jack Shuang Hou: FDA Approves Bayer’s Sunharbo – First Factor XIa Inhibitor for Secondary Stroke Prevention
Jack Shuang Hou, Diagnostic Executive, Microfluidics and Immunoassay Specialist, shared a post on LinkedIn:
“FDA Approves Bayer’s Sunharbo (Asundexian): First Factor XIa Inhibitor for Secondary Stroke Prevention
⠀
This approval introduces a new class of antithrombotic therapy for adults following non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA).
⠀
1. Landmark Phase 3 Clinical Evidence
⠀
OCEANIC-STROKE randomized 12,327 patients, with results published in The New England Journal of Medicine.
⠀
Asundexian 50 mg once daily plus antiplatelet therapy demonstrated:
- 26% relative reduction in ischemic stroke risk versus antiplatelet therapy alone.
- Similar rates of ISTH major bleeding.
- Consistent efficacy across key patient subgroups.
2. A Differentiated Antithrombotic Mechanism
Selective FXIa inhibition aims to suppress pathological thrombus formation while preserving physiological hemostasis.
⠀
3. Global Regulatory Momentum
⠀
Following FDA Priority Review, asundexian has secured U.S. approval alongside China’s NMPA approval.
⠀
Leadership Perspective
⠀
Christian Rommel of Bayer highlighted the potential to address persistent gaps in secondary stroke prevention.
⠀
My Takeaway
⠀
The breakthrough is not simply stronger anticoagulation, but potentially separating antithrombotic efficacy from bleeding risk.
⠀
This represents a paradigm shift in coagulation pathway targeting.
Real-world evidence will be important to establish long-term benefit-risk profiles and optimize patient selection.”
Stay updated with Hemostasis Today.
-
Nov 14, 2026, 09:42Samwel Mikaye: What Every Patient Should Know About DVT Symptoms and Treatment
-
Nov 14, 2026, 09:37Chronic Preoperative Corticosteroid Use and Postoperative Venous Thromboembolism Risk – Thrombosis and Haemostasis Journal
-
Nov 14, 2026, 09:30Ney Carter Borges: Vulnerable Plaque – Imaging and Clinical Significance
-
Nov 14, 2026, 09:25Carmelo Raffo: How Much Antithrombotic Therapy is Truly Necessary after LAAC?
-
Nov 14, 2026, 09:19Mary Cushman: Excellent to Have Jordan Shavit Visit Us for a Virtual Lab Meeting Today
-
Nov 14, 2026, 09:15Chancellor Donald: Heading to ASH 2026 in New Orleans? Let’s Connect on Faculty Opportunities at Tulane
-
Nov 14, 2026, 09:11Sajja Venkatesh: FDA Approved Asundexian, the First Factor XIa Inhibitor
-
Nov 14, 2026, 09:05Selina Evans: How Can Hospitals Make VTE Risk Assessment and Prevention Truly Routine?
-
Nov 14, 2026, 09:01Abdul Rehman Abid: DAPT vs Aspirin Monotherapy Beyond 12 Months Following Drug-Eluting Stent Implantation